| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/21/2004 | WO2003080638A3 Antisense iap nucleobase oligomers and uses thereof |
| 05/21/2004 | WO2003072040A3 Administration of agents for the treatment of inflammation |
| 05/21/2004 | WO2003055440A8 Compositions and methods for the treatement of immune related diseases |
| 05/21/2004 | WO2003042362A8 PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR |
| 05/21/2004 | WO2003020240A3 Therapeutic agent delivery tampon |
| 05/21/2004 | WO2003006001B1 ss-ADRENERGIC BLOCKADE REVERSAL OF CATABOLISM AFTER SEVERE BURN |
| 05/21/2004 | WO2003005493A8 Apparatus for a quick release safety connector assembly |
| 05/21/2004 | WO2002102306A8 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy |
| 05/21/2004 | WO2002014467A8 Cng2b: a putative human cyclic nucleotide-gated ion channel |
| 05/21/2004 | WO2000066068A3 Method for inducing growth and enhancing survival of nervous tissue |
| 05/21/2004 | CA2505476A1 Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| 05/21/2004 | CA2505218A1 Methods and systems for enabling and stabilizing tooth movement |
| 05/21/2004 | CA2504283A1 Therapeutic compositions for drug delivery to and through covering epithelia |
| 05/21/2004 | CA2504028A1 Methods for the treatment, prevention and management of macular degeneration |
| 05/21/2004 | CA2503561A1 Prevention and treatment of synucleinopathic disease |
| 05/21/2004 | CA2502979A1 Pharmaceutical composition comprising a cdk inhibitor and gemcitabine |
| 05/21/2004 | CA2501523A1 Human type ii diabetes gene-kv channel-interacting protein (kchip1) located on chromosome 5 |
| 05/21/2004 | CA2499719A1 Use of tacrolimus (fk506) derivatives combined with beta2-agonists for the treatment of asthma |
| 05/21/2004 | CA2486095A1 Abuse-resistant opioid dosage form |
| 05/21/2004 | CA2484936A1 Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands |
| 05/20/2004 | US20040097867 Systems and methods for treating patients with processed lipoaspirate cells |
| 05/20/2004 | US20040097591 Increasing testosterone levels; sexual dysfunction; kits |
| 05/20/2004 | US20040097583 Use of inhibitors of the sodium/hydrogen exchanger for the treatment of thrombotic and inflammatory disorders |
| 05/20/2004 | US20040097582 Contacting abdominal organ with a blood-flow to abdominal organ decrease preventing agent for negating or reducing decrease in blood flow in an abdominal organ which would otherwise have decreased oxygen delivery because of decreased |
| 05/20/2004 | US20040097577 Use of at least one of melatonin, a melatonin analogue, or a pharmaceutically acceptable salt of melatonin or melatonin analogue, in the preparation of a medicament for the treatment of ADHD in a mammal, especially a human being |
| 05/20/2004 | US20040097573 Use of a COX-2 inhibitor and a NK-1 receptor antagonist for the manufacture of a medicament for the treatment or prevention of inflammatory disorders |
| 05/20/2004 | US20040097555 Useful as a prophylactic or therapeutic agent of the diseases such as rheumatism, arthritis and the like, and other diseases |
| 05/20/2004 | US20040097551 As inhibitors of glucosylceramide synthase; for therapy and prophylaxis |
| 05/20/2004 | US20040097546 For therapy of obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction |
| 05/20/2004 | US20040097544 Use of an inhibitor of the Na+/H+ exchanger for the production of a medicament for the treatment or prophylaxis of disturbances of the central nervous system |
| 05/20/2004 | US20040097540 Adenosine a2a receptor antangonists combined with neurotrophic activity compounds in the treatment of parkinson's disease |
| 05/20/2004 | US20040097538 Therapy of cardiovascular, cerebral vascular, or peripheral vascular disease in a mammal in need thereof, by providing mammal with an effective amount of a rapamycin |
| 05/20/2004 | US20040097536 Extended release oral dosage composition |
| 05/20/2004 | US20040097526 Using triazolo(4,5-d)pyrimidine derivatives or a pharmaceutically acceptable salt or prodrug, in manufacture of a medicament for therapy or prevention of a disorder in which blocking of purine receptors may be beneficial |
| 05/20/2004 | US20040097524 For therapy and prophylaxis of disorder in which the blocking of purine receptors, particularly adenosine receptors and more may be beneficial, such a Parkinson's disease or depression, cognitive or memory impairment, pain |
| 05/20/2004 | US20040097519 Novel salt and crystalline forms of (2r)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber- 5-yl)piperazin-1-yl]- 2-hydroxypropoxy}quinoline |
| 05/20/2004 | US20040097513 Novel non-imidazole compounds |
| 05/20/2004 | US20040097512 Antibiotic compositions for treatment of the eye, ear and nose |
| 05/20/2004 | US20040097507 Useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by multidrug resistance protein MRP1 |
| 05/20/2004 | US20040097501 Triazole compounds useful as protein kinase inhibitors |
| 05/20/2004 | US20040097500 Compounds and compositions for delivering active agents |
| 05/20/2004 | US20040097487 To inhibits matrix metalloprotease activity |
| 05/20/2004 | US20040097486 Administering a pharmaceutically effective amount of a formulation comprising an H1 antagonist and a safe steroid for therapy of ocular conditions in mammals selected from vernal keratoconjunctivitis, giant papillary conjunctivitis |
| 05/20/2004 | US20040097482 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
| 05/20/2004 | US20040097472 Complexes of phosphate derivatives |
| 05/20/2004 | US20040097470 Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals |
| 05/20/2004 | US20040097463 Administering to a subject in need of such treatment an amount of a formulation comprising an isolated molecule selected from the group consisting of asiatic acid and asiaticoside |
| 05/20/2004 | US20040097457 Protein disulfide isomerase and abc transporter homologous proteins involved in the regulation of energy homeostasis |
| 05/20/2004 | US20040097456 Using a cytokine for prophylaxis, therapy and diagnosis of skin related growth disorders in mammals |
| 05/20/2004 | US20040097438 Fused-ring compounds and use thereof as drugs |
| 05/20/2004 | US20040097437 Sequential therapy comprising a 20(S)-camptothecin and an anthracycline |
| 05/20/2004 | US20040097424 Antilipemic agents; anticholesterol agents; cardiovascular disorders; antidiabetic agents |
| 05/20/2004 | US20040097420 Proteasome regulation of NF-kB activity |
| 05/20/2004 | US20040097415 Controlling blood glucose concentration; amylin antagonist |
| 05/20/2004 | US20040097404 Supplement to be enternally administered for parenteral nutrition or partial enteral/oral nurtrition of the critically ill, the chronically ill and people with malnutrition |
| 05/20/2004 | US20040097403 Linkable sialyl lewis x analogs |
| 05/20/2004 | US20040097402 Therapy for infections; bactericides; synergistic mixtures |
| 05/20/2004 | US20040096971 Using cortical and/or medullary thymic epithelial cells to propagate lymphocytes and generate T cells from hematopoietic stem cells |
| 05/20/2004 | US20040096939 Modifier of organelle metabolism |
| 05/20/2004 | US20040096925 Identifying enzyme inhibitors for treatment of skin, allergic and inflammatory disorders; cosmetics |
| 05/20/2004 | US20040096894 Three dimensional structure of cell surface glycoprotein for screening and designing drugs for treatment of inflammation |
| 05/20/2004 | US20040096888 Comprises nucleotide sequences coding cyclin dependent kinase (PELOTA) for diagnosis, treatment, prognosis and prevention of cell proliferative, cardoivascular, inflammatory, arthritic disorders |
| 05/20/2004 | US20040096886 Using sodium channel (SCNA) expresion to detect nervous system disorders; antitpileptic agents |
| 05/20/2004 | US20040096885 Using sodium channel (SCNA) expresion to detect nervous system disorders; antitpileptic agents |
| 05/20/2004 | US20040096848 Oligomeric compounds for the modulation HIF-1alpha expression |
| 05/20/2004 | US20040096845 Peritoneal dialysates |
| 05/20/2004 | US20040096816 Method of indentifying an eventual modification of at least one biological parameter implementing young and aged living cells |
| 05/20/2004 | US20040096815 Comprises compared proteomic and/or compared transcriptomic and/or compared genomic analysis; enzyme-linked immunosorbent assay (ELISA) |
| 05/20/2004 | US20040096523 Reduces ability of mammal's leukocytes or platelets to become activated; administering potentiating compound; preventing nonpulmonary ischemia- reperfusion injury |
| 05/20/2004 | US20040096522 Synergistic mixtures |
| 05/20/2004 | US20040096521 Topical applying aspirin solutions |
| 05/20/2004 | US20040096518 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 05/20/2004 | US20040096513 Systemically minimizing the inflammatory effects of TNF- alpha are disclosed. The compositions include particles of bioactive glass with a particle size less than about 20 mu m, alone or in combination with anti-inflammatory agents and |
| 05/20/2004 | US20040096487 Treating healed wounds including hypertrophic scars so as to prevent scarring or reduce the size and improve the appearance of scars comprises applying to the healed wound or scar a composition comprising a fluid, film-forming carriers |
| 05/20/2004 | US20040096442 Modified anti-egfr antibodies with reduced immunogenicity |
| 05/20/2004 | US20040096436 Method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a member selected from an inhibitor of a protein kinase, an enantiomer of such a compound, a prodrug of such a |
| 05/20/2004 | US20040096435 Methods for screening compounds that modulate lipid metabolism |
| 05/20/2004 | US20040096431 Providing a tissue removal system; removing adipose tissue from a patient using the tissue removal system, the adipose tissue having a concentration of stem cells; processing at least a part of the adipose tissue to obtain a concentration |
| 05/20/2004 | US20040096423 Use of a triple combination comprising a 5ht3 antagonist, a 5ht4agonist and a laxative for promoting intestinal lavage |
| 05/20/2004 | US20040096399 Inhalers containing a solution of an active ingredient in a hydrofluorocarbon propellant and a cosolvent; the internal surfaces consist of stainless steel, anodised aluminium or are lined with an inert organic coating. |
| 05/19/2004 | EP1420025A1 Powder comprising water-containing beta-maltose crystals and production process and use thereof |
| 05/19/2004 | EP1419803A2 Pharmaceutical composition for topical administration comprising an antiviral substance and a glucocorticoid |
| 05/19/2004 | EP1419785A1 Drugs containing chymase inhibitor and ace inhibitor as the active ingredients |
| 05/19/2004 | EP1419783A2 Use of a composition comprising an exendin or a compound derived therefrom and a pharmaceutical carrier |
| 05/19/2004 | EP1419782A1 Use of consensus interferon for reducing the side-effects of interferon treatment in viral hepatitis |
| 05/19/2004 | EP1419778A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| 05/19/2004 | EP1419766A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 05/19/2004 | EP1419765A1 Process for manufacturing a solid dosage form comprising an effervescent couple for buccal, gingival or sublingual administration |
| 05/19/2004 | EP1419764A1 Use of an association of synergic calcium channel blocker agents for preventing or treating wrinkles and fine lines |
| 05/19/2004 | EP1419264A2 Kinases and phosphatases |
| 05/19/2004 | EP1419173A2 Peptides that bind to atherosclerotic lesions |
| 05/19/2004 | EP1419162A1 Substituted-aryl 7-aza 2.2.1]bicycloheptanes for the treatment of disease |
| 05/19/2004 | EP1419152A1 Hiv inhibiting pyrimidines derivatives |
| 05/19/2004 | EP1419143A1 24-sulfur-substituted analogs of 1alpha,25-dihydroxy vitamin d3 |
| 05/19/2004 | EP1418949A2 Inhibitor of dna methylation |
| 05/19/2004 | EP1418936A2 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio. |
| 05/19/2004 | EP1418935A1 Genobix agonists and antagonists for use in the treatment of metabolic disorders |
| 05/19/2004 | EP1418922A1 Compositions comprising negatively charched phospholipids for treatment and/or prevention of macular degeneration and method for its manufacture |
| 05/19/2004 | EP1418920A1 As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| 05/19/2004 | EP1418918A2 Compositions and methods for targeting cerebral circulation and treatment of headache |